Citadel Advisors
HZNP

Citadel Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Citadel Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-937,800
Closed -$108M – 15762
2023
Q3 		$108M Sell
937,800
-273,100
-23% -$29.3M 0.02% 598
2023
Q2 		$125M Buy
1,210,900
+1,193,200
+6,741% +$126M 0.03% 502
2023
Q1 		$1.93M Sell
17,700
-265,900
-94% -$29.4M ﹤0.01% 5455
2022
Q4 		$32.3M Buy
283,600
+222,700
+366% +$18.5M 0.01% 1489
2022
Q3 		$3.77M Sell
60,900
-40,100
-40% -$2.8M ﹤0.01% 4359
2022
Q2 		$8.06M Buy
101,000
+19,400
+24% +$1.84M ﹤0.01% 2966
2022
Q1 		$8.59M Buy
81,600
+16,100
+25% +$1.57M ﹤0.01% 3213
2021
Q4 		$7.06M Sell
65,500
-7,100
-10% -$775K ﹤0.01% 3703
2021
Q3 		$7.95M Buy
72,600
+12,000
+20% +$1.25M ﹤0.01% 3462
2021
Q2 		$5.67M Sell
60,600
-71,400
-54% -$6.57M ﹤0.01% 4165
2021
Q1 		$12.1M Sell
132,000
-30,700
-19% -$2.59M ﹤0.01% 2691
2020
Q4 		$11.9M Buy
162,700
+58,900
+57% +$4.38M ﹤0.01% 2422
2020
Q3 		$8.06M Buy
103,800
+73,500
+243% +$5.06M ﹤0.01% 2551
2020
Q2 		$1.68M Buy
30,300
+1,100
+4% +$47.1K ﹤0.01% 4875
2020
Q1 		$865K Sell
29,200
-32,800
-53% -$1.11M ﹤0.01% 5589
2019
Q4 		$2.24M Buy
62,000
+3,200
+5% +$98.1K ﹤0.01% 4223
2019
Q3 		$1.6M Sell
58,800
-3,400
-5% -$87.9K ﹤0.01% 4829
2019
Q2 		$1.5M Sell
62,200
-31,300
-33% -$794K ﹤0.01% 5022
2019
Q1 		$2.47M Buy
93,500
+31,100
+50% +$737K ﹤0.01% 4103
2018
Q4 		$1.22M Sell
62,400
-61,900
-50% -$1.21M ﹤0.01% 5004
2018
Q3 		$2.43M Buy
124,300
+61,300
+97% +$1.17M ﹤0.01% 4072
2018
Q2 		$1.04M Buy
63,000
+9,000
+17% +$137K ﹤0.01% 5147
2018
Q1 		$767K Sell
54,000
-47,900
-47% -$708K ﹤0.01% 5209
2017
Q4 		$1.49M Sell
101,900
-30,500
-23% -$428K ﹤0.01% 4044
2017
Q3 		$1.68M Buy
132,400
+66,300
+100% +$843K ﹤0.01% 3611
2017
Q2 		$785K Sell
66,100
-38,800
-37% -$483K ﹤0.01% 4457
2017
Q1 		$1.55M Sell
104,900
-157,500
-60% -$2.55M ﹤0.01% 3385
2016
Q4 		$4.25M Buy
262,400
+76,300
+41% +$1.38M ﹤0.01% 2165
2016
Q3 		$3.37M Buy
186,100
+47,800
+35% +$934K ﹤0.01% 2379
2016
Q2 		$2.28M Buy
138,300
+41,600
+43% +$673K ﹤0.01% 2607
2016
Q1 		$1.6M Sell
96,700
-3,100
-3% -$54.2K ﹤0.01% 2902
2015
Q4 		$2.16M Buy
99,800
+8,600
+9% +$167K ﹤0.01% 2652
2015
Q3 		$1.81M Sell
91,200
-4,100
-4% -$130K ﹤0.01% 3072
2015
Q2 		$3.31M Buy
95,300
+36,100
+61% +$1.1M ﹤0.01% 2480
2015
Q1 		$1.54M Buy
59,200
+45,500
+332% +$834K ﹤0.01% 3408
2014
Q4 		$177K Sell
13,700
-4,500
-25% -$56.3K ﹤0.01% 6114
2014
Q3 		$223K Buy
18,200
+2,700
+17% +$31.4K ﹤0.01% 5616
2014
Q2 		$245K Buy
15,500
+1,500
+11% +$21.4K ﹤0.01% 5324
2014
Q1 		$212K Buy
14,000
+2,900
+26% +$32.8K ﹤0.01% 5457
2013
Q4 		$85K Sell
11,100
-2,700
-20% -$14.6K ﹤0.01% 5734
2013
Q3 		$47K Sell
13,800
-15,000
-52% -$39.5K ﹤0.01% 5827
2013
Q2 		$71K Buy
+28,800
New +$69.1K ﹤0.01% 5459

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $247M AUM 21.93% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Citadel Advisors's HZNP Position: Q4 2023 in Review

Citadel Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 4,149,825 shares — an estimated $480M sold.

Citadel Advisors first reported a position in HZNP in Q2 2013 and held it in 41 quarters. The position peaked at $480M in Q3 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Citadel Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Citadel Advisors sold 4,149,825 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $480M.
  • Citadel Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2013 and held it in 41 quarters.
  • Citadel Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $480M in Q3 2023.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Citadel Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.